<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<HTML><HEAD>
<META HTTP-EQUIV="Content-Type" CONTENT="text/html; charset=us-ascii">
<TITLE>Message</TITLE>
<META content="MSHTML 6.00.2800.1264" name=GENERATOR></HEAD>
<BODY hb_focus_attach="true">
<DIV>
<P class=RefCommentaryHeading style="MARGIN: 0in 0in 0pt"><?xml:namespace prefix
= o ns = "urn:schemas-microsoft-com:office:office" /><o:p> <SPAN
class=904474319-13102003><FONT face="Comic Sans MS" color=#0000ff>This is from
the March 2003 checklist.............................</FONT></SPAN></o:p></P>
<P class=QuestionNumber style="MARGIN: 0in 0in 0pt"><STRONG>ANP.22570<SPAN
style="mso-spacerun: yes">
</SPAN>Phase II<SPAN
style="mso-tab-count: 1">
</SPAN>N/A<SPAN style="mso-spacerun: yes"> </SPAN>YES<SPAN
style="mso-spacerun: yes"> </SPAN>NO</STRONG></P>
<P class=QuestionNumber
style="MARGIN: 0in 0in 0pt"><o:p><STRONG> </STRONG></o:p></P>
<P class=Note style="MARGIN: 0in 0in 0pt"><STRONG>Are negative controls used for
each antibody species?<o:p></o:p></STRONG></P>
<P class=Note style="MARGIN: 0in 0in 0pt"><B
style="mso-bidi-font-weight: normal"><o:p> </o:p></B></P>
<P class=Note style="MARGIN: 0in 0in 0pt"><I
style="mso-bidi-font-style: normal">NOTE:<SPAN style="mso-spacerun: yes">
</SPAN>A negative control for each primary antibody species must be used.<SPAN
style="mso-spacerun: yes"> </SPAN>Alternatively, buffer controls can be
used if multiple antibodies for each species are included.<SPAN
style="mso-spacerun: yes"> </SPAN>The controls used should also control
for pre-treatment conditions. <o:p></o:p></I></P>
<P class=QuestionNumber
style="MARGIN: 0in 0in 0pt"><o:p><STRONG> </STRONG></o:p></P>
<P class=RefCommentaryHeading style="MARGIN: 0in 0in 0pt">COMMENTARY:</P>
<P class=RefCommentaryHeading style="MARGIN: 0in 0in 0pt"><o:p> </o:p></P>
<P class=MsoNormal style="MARGIN: 0in 0in 0pt">A negative control for each
primary antibody species must be used.<SPAN style="mso-spacerun: yes">
</SPAN>Alternatively, buffer controls can be used if multiple antibodies for
each species are included.<SPAN style="mso-spacerun: yes"> </SPAN>The
controls used should also control for pre-treatment conditions.</P>
<P class=RefCommentaryHeading style="MARGIN: 0in 0in 0pt"><o:p> </o:p></P>
<P class=Reference style="MARGIN: 0in 0in 0pt">REFERENCE: Weirauch M.
Multitissue control block for immunohistochemistry. <I
style="mso-bidi-font-style: normal">Lab Med.</I> 1999;30:448-449. </P>
<P class=RefCommentaryHeading
style="MARGIN: 0in 0in 0pt"><o:p> </o:p></P></DIV>
<DIV> </DIV>
<DIV> </DIV><!-- Converted from text/plain format -->
<P><FONT size=2>Hazel Horn, HT/HTL (ASCP)<BR>Histology Supervisor<BR>Arkansas
Children's Hospital<BR><BR>Phone - 501.364.4240<BR>Fax - 501.364.3912
</FONT></P>
<BLOCKQUOTE style="MARGIN-RIGHT: 0px">
<DIV></DIV>
<DIV class=OutlookMessageHeader lang=en-us dir=ltr align=left><FONT
face=Tahoma size=2>-----Original Message-----<BR><B>From:</B> Patti Loykasek
[mailto:ploykasek@phenopath.com] <BR><B>Sent:</B> Monday, October 13, 2003
10:52 AM<BR><B>To:</B> histonet<BR><B>Subject:</B> [Histonet] IHC
QC's<BR><BR></FONT></DIV><FONT face=Verdana>I'm glad that everyone is so
concerned with both negative and positive IHC controls. There is certainly
more than one side to this issue. I will say that I don't think a positive QC
on every slide is absolutely necessary, for many reasons. If the QC is rare
& precious, then it is a waste of resources. As is running a negative
control for every possible technique permutation on small amounts of tumor. I
would rather have slides with tumor left for additional studies than have
wasted tumor sections on 4-6 negative controls. You can always evaluate
non-specific staining on slides that have had an antibody applied & that
are negative with that antibody. The CAP is specific that positive controls be
used for each antibody - see CAP checklist ANP.22550. They do not
specify for each slide. Since positive QC's should be kept filed for the same
number of years as the patient slide & records, it should be possible to
pull a QC slide from the IHC run for a particular slide. In the CAP comment on
ANP.22550, the use of internal QC's is also mentioned. Although there are many
ways of dealing with the issue of QC's, I'm sure we all want to do what is
prudent, abide by the regulations, and increase the level of patient care.
<BR>Just my 2 cents worth. <BR><BR>Patti Loykasek<BR>Phenopath
Laboratories<BR>Seattle, WA</FONT> </BLOCKQUOTE>
<P></P>
<DIV><P><HR>
The information contained in this message may be privileged and confidential and protected from disclosure. If the reader of this message is not the intended recipient, or an employee or agent responsible for delivering this message to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by replying to the message and deleting it from your computer. Thank you. Arkansas Children's Hospital
</P></DIV>
</BODY></HTML>